Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy
- 23 July 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (4), 516-519
- https://doi.org/10.1182/blood.2020004907
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta‐analysisHepatology, 2017
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013The Lancet, 2015
- Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP ChemotherapyJAMA, 2014
- Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapyHematology, 2014
- Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective StudyJournal of Clinical Oncology, 2014
- Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis BJournal of Clinical Oncology, 2013
- Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort studyThe Lancet Oncology, 2010
- Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- Risk of Hepatitis B Virus Reactivation in Patients Who Are Hepatitis B Surface Antigen Negative/Antibody to Hepatitis B Core Antigen Positive and the Role of Routine Antiviral ProphylaxisJournal of Clinical Oncology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009